BioStock: Lipum recruits new CMO – “I have been following their research for a while and am impressed”
In preparation for the continued clinical development of SOL-116 in rheumatoid arthritis, Lipum has strengthened its management team by appointing Peter Hovstadius as the new Chief Medical Officer. Peter brings extensive experience in clinical drug development from leading roles at companies such as XNK Therapeutics, Novartis, and MSD.
– It is important for me to work in an organisation that not only has great ideas but also the capacity to turn those ideas into reality, and always with the patient in mind, says Peter in an interview.
Read the full article at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se